Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) EBT Margin: 2021-2025

Historic EBT Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to 27,873.57%.

  • SAB Biotherapeutics' EBT Margin rose 1461122.00% to 27,873.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 68,111.45%, marking a year-over-year increase of 7128757.00%. This contributed to the annual value of -3,171.70% for FY2024, which is 128720.00% down from last year.
  • Per SAB Biotherapeutics' latest filing, its EBT Margin stood at 27,873.57% for Q3 2025, which was up 83.33% from 15,203.74% recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year EBT Margin high stood at 27,873.57% for Q3 2025, and its period low was -8,669.15% during Q4 2024.
  • For the 3-year period, SAB Biotherapeutics' EBT Margin averaged around 3,876.17%, with its median value being -532.06% (2024).
  • Per our database at Business Quant, SAB Biotherapeutics' EBT Margin crashed by 796,947bps in 2023 and then soared by 1,799,143bps in 2025.
  • Over the past 5 years, SAB Biotherapeutics' EBT Margin (Quarterly) stood at -104.46% in 2021, then tumbled by 25,877bps to -363.23% in 2022, then tumbled by 713,052bps to -7,493.75% in 2023, then crashed by 117,540bps to -8,669.15% in 2024, then surged by 1,461,122bps to 27,873.57% in 2025.
  • Its EBT Margin stands at 27,873.57% for Q3 2025, versus 15,203.74% for Q2 2025 and 15,495.10% for Q1 2025.